Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, 1 Xinsi Road, Xi'an, 710038, China.
Department of Thoracic Surgery, 1st Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
BMC Cancer. 2023 Jul 24;23(1):696. doi: 10.1186/s12885-023-11171-z.
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors with a high prevalence and poor prognosis. It is an urgent problem to deeply understand the molecular mechanism of ESCC and develop effective diagnostic and prognostic methods.
Using tumor tissue and corresponding paracancerous samples from 141 resected ESCC patients, we assessed Jumonji domain-containing protein 6 (JMJD6) expression using Immunohistochemical (IHC) staining. Kaplan-Meier survival analysis and univariate or multivariate analysis were used to investigate the relationship between JMJD6 expression and clinicopathological features. The expression status and prognostic value of JMJD6 were analyzed by bioinformatics and enrichment analysis.
The expression of JMJD6 in ESCC samples was higher than that in the corresponding paracancerous samples, and high expression of JMJD6 was positively associated with poor prognosis of ESCC patients. In addition, bioinformatics analysis of the expression and prognosis of JMJD6 in a variety of tumors showed that high expression of JMJD6 was significantly associated with poor overall survival (OS) in ESCC patients. Enrichment analysis indicated that the high expression of genes similar to JMJD6, such as Conserved oligomeric Golgi 1(COG1), Major facilitator superfamily domain 11 (MFSD11) and Death Effector Domain Containing 2 (DEDD2), was associated with poor prognosis of ESCC, suggesting that JMJD6 might be involved in the occurrence and prognosis of ESCC.
Our study found that JMJD6 expression was significantly increased in ESCC patients and positively correlated with prognosis, indicating that targeting JMJD6 might be an attractive prognostic biomarker and provides a potential treatment strategy for ESCC.
The study was approved by Tangdu Hospital ethics committee (No. TDLL-202110-02).
食管鳞状细胞癌（ESCC）是最常见的恶性肿瘤之一，具有较高的发病率和较差的预后。深入了解 ESCC 的分子机制并开发有效的诊断和预后方法是一个亟待解决的问题。
使用 141 例接受根治性手术的 ESCC 患者的肿瘤组织及其对应的癌旁组织样本，采用免疫组织化学（IHC）染色法评估 Jumonji 结构域包含蛋白 6（JMJD6）的表达。采用 Kaplan-Meier 生存分析及单因素或多因素分析方法，探讨 JMJD6 表达与临床病理特征的关系。采用生物信息学和富集分析方法，分析 JMJD6 的表达状态和预后价值。
ESCC 组织中 JMJD6 的表达高于相应的癌旁组织，且 JMJD6 的高表达与 ESCC 患者的预后不良呈正相关。此外，JMJD6 在多种肿瘤中的表达和预后的生物信息学分析表明，JMJD6 的高表达与 ESCC 患者的总生存（OS）显著相关。富集分析表明，与 JMJD6 表达相似的基因（如 Conserved oligomeric Golgi 1（COG1）、Major facilitator superfamily domain 11（MFSD11）和 Death Effector Domain Containing 2（DEDD2））的高表达与 ESCC 的不良预后相关，提示 JMJD6 可能参与 ESCC 的发生和预后。
本研究发现 JMJD6 在 ESCC 患者中表达显著增加，并与预后呈正相关，提示靶向 JMJD6 可能是一种有吸引力的预后生物标志物，并为 ESCC 提供了一种潜在的治疗策略。
本研究经唐都医院伦理委员会批准（编号：TDLL-202110-02）。
